**Imaging of Bone Sarcomas and Soft-Tissue Sarcomas**

**Bildgebung von Knochen- und Weichteilsarkomen**

**Authors**
Jasminka Igrec, Michael H. Fuchsjäger

**Affiliation**
Division of General Radiological Diagnostics, Department of Radiology, Hospital of the Federal State of Styria and University Hospital Graz, Austria

**Key words**
bone sarcoma, soft tissue sarcoma, MR-imaging, ultrasound computed tomography (US/CT), radiomics, radiography

**received** 12.09.2020
**accepted** 09.02.2021
**published online** 2021

**Bibliography**
Fortschr Röntgenstr
DOI 10.1055/a-1401-0215
ISSN 1438-9029
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

**Correspondence**
Dr. Jasminka Igrec
Universitätsklinik für Radiologie, Klinische Abteilung für Allgemeine Radiologische Diagnostik, Medizinische Universität Graz, Auenbruggerplatz 9, 8010 Graz, Austria
Tel.: +43/3 16/38 58 04 34
jasmina.igrec@medunigraz.at

**ZUSAMMENFASSUNG**

**Hintergrund**  
Bei der Diagnose von Knochen- und Weichteilsarkomen hat die kontinuierliche Weiterentwicklung verschiedener bildgebender Verfahren die Erkennung kleiner Läsionen, die chirurgische Planung, die Beurteilung chemotherapeutischer Effekte und, was wichtig ist, die Anleitung für die Operation oder Biopsie verbessert.

**Methode**  

**Ergebnisse und Schlussfolgerung**  
Wie in dieser Übersicht diskutiert, spielen Radiografie, Ultraschall, CT und MRI eine Schlüsselrolle bei der bildgebenden Beurteilung von Knochen- und Weichteilsarkomen. In der täglichen Praxis ergänzen fortgeschrittene MRT-Techniken die Standard-MRT, werden aber nach wie vor zu wenig genutzt, da sie als zeitaufwändig, technisch anspruchsvoll und nicht zuverlässig genug angesehen werden, um Biopsie und Histologie zu ersetzen. PET/MRI und Radiomics haben sich als vielversprechend erwiesen, um in Zukunft zur Bildgebung von Sarkomen beizutragen.

**Kernaussagen:**  
- Röntgenbilder sind bei diagnostischen Bildgebungsalgorithmen für Sarkome nach wie vor von entscheidender Bedeutung.
- US ist eine erste bildgebende Studie zur Beurteilung von oberflächlichen Weichteiltumoren.
- Die Rolle der CT entwickelt sich mit dem Entstehen neuer Techniken ständig weiter.
- Die MRT ermöglicht die nichtinvasive Beurteilung von Weichteil-, Knochen- und Gelenkstrukturen.
- Maschinelle Lernmethoden könnten die personalisierte Auswahl der Therapie für Patienten mit Sarkom verbessern.

**ABSTRACT**

**Background**  
In the diagnosis of bone and soft-tissue sarcomas, the continuous advancement of various imaging modalities has improved the detection of small lesions, surgical planning, assessment of chemotherapeutic effects, and, importantly, guidance for surgery or biopsy.

**Method**  
This review was composed based on a PubMed literature search for the terms “bone sarcoma,” “bone cancer” and “soft tissue sarcoma,” “imaging,” “magnetic resonance imaging,” “computed tomography,” “ultrasound,” “radiography,” and “radiomics” covering the publication period 2005–2020.

**Results and Conclusion**  
As discussed in this review, radiography, ultrasound, CT, and MRI all play key roles in the imaging evaluation of bone and soft-tissue sarcomas. In daily practice, advanced MRI techniques complement standard MRI but remain underused, as they are considered time-consuming, technically challenging, and not reliable enough to replace biopsy and histology. PET/MRI and radiomics have shown promise regarding the imaging of sarcomas in the future.

**Key Points:**
- Radiographs remain crucial in diagnostic imaging algorithms for sarcomas.
- US is an initial imaging study for the evaluation of superficial soft-tissue tumors.
- The role of CT continues to evolve as new techniques emerge.
Introduction

Bone and soft-tissue sarcomas represent a large, diverse group of mesenchymal-derived malignancies. According to the National Comprehensive Cancer Network (NCCN) guidelines, a multidisciplinary approach to the management of patients with primary bone and soft-tissue tumors is needed to achieve optimal results [1, 2].

In general, therapy is interdisciplinary and includes radiation therapy, systemic therapy, and surgery. Tumor response to systemic treatment correlates with the long-term prognosis, and its assessment is essential for planning future treatment.

Imaging, which is performed prior to any intervention, plays a crucial role in diagnosis, staging and restaging, monitoring response to treatment, and surveillance for recurrence. A radiological report is the cornerstone of the communication between radiology and the multidisciplinary team. Hence, it must be standardized, should describe the key findings that aid in planning further treatment, and should indicate the assumed etiology, providing a differential diagnosis in the case of equivocal findings. (Table 1).

Due to the large variety of sarcoma subtypes, tumor features and treatment plans vary, and there is no single diagnostic pathway that determines the exact role of a particular imaging study (Table 2).

Imaging techniques are rapidly evolving to address new and individualized treatment regimens [3–8] (Table 3). In addition to conventional MRI (cMRI) sequences, advanced MRI techniques, including diffusion-weighted imaging (DWI), chemical shift imaging (CSI), dynamic contrast-enhanced MRI (DCE-MRI), MR spectroscopy (MRS), diffusion tensor imaging (DTI) are being assessed for sarcoma imaging.

However, these advanced imaging techniques are not ubiquitously accessible, and thus their exact roles have yet to be established.

This review focuses on using different imaging methods for the detection, characterization, local staging, and response assessment of primary bone and soft-tissue sarcomas.

Soft-tissue sarcomas

Soft-tissue sarcomas (STS) are uncommon tumors that account for roughly 1% of solid cancers in adults, affecting all age groups. They represent a diverse group of neoplasms, including more than 80 different histological subtypes. This group displays a unique growth pattern, with a tendency to spread along fascial planes and within compartments in the line of least resistance [3, 9–11]. Approximately 60% of STSs are localized in the extremities, 19% appear in the trunk wall, 15% in the retroperitoneum, and 9% in the head and neck [12].

The main objectives of imaging are to detect and characterize a soft-tissue mass, to estimate its extent and its relation to adjacent structures within a muscle compartment, to determine the feasibility of resection, and to identify regional lymphadenopathy.

Ultrasound (US) is usually an initial imaging method used for the assessment of superficial soft-tissue tumors. It measures the dimensions and depth of the lesion, determines its relation to the fascia, its internal echotexture, and vascularity (color Doppler), and can differentiate a few typical benign tumors from pseudotumors (e.g., lipomas, ganglion cysts), and sometimes, hematomas and inflammatory collections from other equivocal lesions that need further evaluation. Contrast-enhanced US (CEUS) has recently been assessed for the diagnosis of soft-tissue tumors, especially for evaluating vascular tumor characteristics. Vital tumor in malignancies shows earlier heterogeneous enhancement as compared to benign lesions with homogeneous or no enhancement [13]. The role of US elastography in STS is currently being validated [14].

Conventional radiography (CR), with at least two orthogonal views, is useful for detecting fat-containing lesions due to the displacement of the tissue planes, and for identifying vascular lesions or bone and soft tissue changes as part of inflammatory arthritis such as gout. CR can detect calcification, determine the calcification pattern, or depict the adjacent bone’s pressure erosion [3, 11].

Given the advantages of MRI, concerning radiation exposure and contrast resolution, the applicability of computed tomography (CT) in the local assessment of STS is limited. However, CT has a role in evaluating calcified lesions (i.e., to rule out a myositis ossificans), identifying fat-containing lesions and differentiating calcification from ossification [3, 6]. When indicated, CT with contrast is a useful method for monitoring a local lesion, with comparable accuracy to MRI for the detection of recurrence greater than 15 cm³ [15]. CT perfusion (pCT) imaging is a novel technique that provides both qualitative and quantitative imaging data regarding tumor microcirculation. Functional parameters obtained with pCT could be used as potential biomarkers for tumor response to various anticancer therapies targeting tumor vascularization [7].

MRI has become the cornerstone of musculoskeletal (MSK) radiology in the last decades due to its capacity to noninvasively assess soft-tissue, bone, and articular structures (Fig. 1). The combination of cMRI and advanced MRI (aMRI) sequences enables state-of-the-art imaging of STS.

Delineating the tumor in relation to neurovascular structures, muscular compartments, and adjacent joints and determining the fascia-tumor relationship are essential for preoperative staging and planning of further treatment. MRI provides excellent characterization of tissues and enables adequate evaluation of local tumor extent, which is crucial for delineating safe surgical margins. Regarding the signal characteristics of lesions, Patel divides all soft-tissue masses into four categories (see Table 4) [6].

Citation Format

Table 1 The role of imaging methods in the evaluation of bone and soft-tissue tumors.

<table>
<thead>
<tr>
<th><strong>Table 1</strong> Die Rolle der Bildgebung in der Behandlung von Knochen- und Weichteiltumoren.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ultrasound (US)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>plain radiographs</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>computed tomography (CT)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>CT- PERfusion</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>magnetic resonance imaging (MRI)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Table 2 Checklist of the imaging findings in sarcoma reporting.

<table>
<thead>
<tr>
<th><strong>Table 2</strong> Checkliste von Bildbefunden in der Sarkom-Berichterstellung.</th>
</tr>
</thead>
<tbody>
<tr>
<td>tumor size</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>location of the tumor</td>
</tr>
<tr>
<td>compartmental extent of the mass</td>
</tr>
<tr>
<td>lesion character</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>local invasiveness of the lesion</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>invasion/encasement of the vessels and nerves</td>
</tr>
<tr>
<td>extension to the underlying bone or adjacent joint</td>
</tr>
<tr>
<td>lymph node metastasis</td>
</tr>
<tr>
<td>distant metastasis</td>
</tr>
</tbody>
</table>

For optimal therapy planning, further questions, especially regarding tumor location and extension, need to be addressed.

1. Healthy tissue surrounding STS is one of the crucial determinants of adequate resection margins. A wide excisional margin, defined as a distance of 2 cm from skin, fat, or muscle, and 1 mm from the fascia, is the primary surgical goal. For this reason, the differentiation of the reactive zone of edema from tumor infiltration of the fascia may be of great importance [11]. DCE-MRI and DWI are useful for evaluating tumor spread, especially for differentiating edema from tumor tissue [8]. Yoon et al. suggested adding DWI to cMRI, as it improves reader confidence in fascial involvement assessment [16].
Knochen- und Weichteilsarkomen.

**Table 3** Value of MRI techniques in the diagnosis of bone and soft-tissue sarcomas.

| T1-weighted imaging (T1WI) | bone marrow evaluation  
| characterisation of anatomical relationship between lesion and surrounding structures  
| characterization of lipomatous lesions |
| T2-weighted imaging (T2WI) | tumor characterization – fluid-fluid levels  
| evaluation of fasic planes |
| fat suppression (FS) | detection of fat tissue in a lesion (hemangioma, lipoma)  
| evaluation of the extent of edema  
| increased conspicuousness of tumor vascularization in postcontrast T1WI |
| short tau inversion recovery (STIR) | detection of changes with high T2 signal (tumor, inflammation, hemorrhage)  
| potential pitfall: overestimation of tumor extension |
| susceptibility weighted imaging (SWI)/gradient echo imaging (GE) | identification of increased susceptibility artifacts as evidence of prior hemorrhage (hemoglobin), metal, and air |
| gadolinium contrast enhancement (Gd-CE) | identification of vessels and vascular involvement  
| differentiation of solid hyperintense (myxomatous) or purely cystic lesions  
| differentiation of solid, non-necrotic areas vs. fluid  
| differentiation of edema from viable tumor  
| delineation of hemorrhage (suspicion of underlying soft-tissue tumor)  
| unequivocal findings **abstain from further imaging with Gd if purely lipomatous tumor, anatomical asymmetry, and no tumor identified on the initial three scan sequences (T1w and T2w parallel to longitudinal tumor axis, T1w parallel to axial tumor axis)** |
| subtraction | elimination of misinterpretation of T1 shortening associated with hemorrhagic change as vascular enhancement  
| in patients with metal fixation, no need for FS on postcontrast imaging |
| dynamic contrast-enhanced imaging (DCE-MRI) | differentiation of necrosis  
| differentiation of viable active tumoral tissue vs. nontumoral/necrotic areas – directing biopsy  
| noninvasive assessment of response to radio- and chemotherapy  
| information on tissue perfusion, vascularization, capillary permeability, volume of interstitial space  
| differentiation of tumor vs. peritumoral edema  
| monitoring treatment response: a) after starting neoadjuvant chemotherapy  
| b) during surveillance after surgery |
| 1. intermediate T1WI high T2WI  
| postcontrast enhancement |
| 2. high signal on T1WI high/intermediate T2WI |
| 3. low T1WI and T2WI |
| 4. high T1WI (consistent with) fat suppression equal to fat (frequency-selective FS and short T1 inversion recovery) |

**Table 3** (Continuation)

| chemical shift imaging (CSI) | evaluation of bone marrow infiltration |
| diffusion-weighted imaging (DWI) | qualitative and quantitative assessment of tissue cellularity and cell membrane integrity  
| restriction of diffusion in malignant tumors – differentiation between benign and malignant tumors (pitfall: abscess, peripheral nerve sheath tumors)  
| assessment of response to neoadjuvant therapy (residual vs. recurrent tumor vs. radiation-induced pseudotumor, postoperative granulation tissue, scarring)  
| response to treatment |
| MR spectroscopy (MRS) | largely a research tool  
| elevation of the choline peak in malignant tumors – differentiation of benign from malignant lesions |
| diffusion tensor imaging (DTI) | reliable preoperative information about peripheral nerve involvement in STS |

**Table 4** Characterization of soft tissue lesions on magnetic resonance imaging.

<table>
<thead>
<tr>
<th>MRI signal characteristics</th>
<th>tissue type</th>
<th>diagnosis</th>
</tr>
</thead>
</table>
| 1. intermediate T1WI high T2WI postcontrast enhancement | myxoid | most sarcomas  
| myxoma  
| myxoid liposarcoma  
| other myxoid sarcomas |
| 2. high signal on T1WI high/intermediate T2WI | subacute blood proteinaceous fluid melanin | hemorrhagic tumors  
| lymphangioma/slow-flow vascular malformation melanoma/clear cell sarcoma |
| 3. low T1WI and T2WI | fibrous hemosiderin calcification | highly cellular malignancies  
| (e.g., lymphoma) |
| 4. high T1WI (consistent with fat) fat suppression equal to fat (frequency-selective FS and short T1 inversion recovery) | lipomatous | liposarcoma (when conventional lipoma/ lipoma variants and hemangioma excluded):  
| well-differentiated  
| dedifferentiated  
| pleomorphic – may not have any visible fat |
2. Additionally, cMRI has its limits with respect to distinguishing residual tumor from reactive changes after neoadjuvant therapy, as both residual tumor and posttreatment scar tissue enhance after injection of contrast. DCE-MRI overcomes this problem in the pre- or posttreatment setting by providing information about the tissue's vascular properties by discriminating different contrast enhancement patterns. Utilizing a gradient-echo (GE) sequence after dynamic Gd injection enables differentiation of rapid enhancement of viable tumor tissue from non-enhancing necrosis, late-enhancing posttherapy changes, peritumoral edema, or granulation tissue [8, 17].

3. In STS, tumor size, location, depth, and the French Federation of Cancer Centers Sarcoma Group (FNCLCC) histologic grading system (based on tumor differentiation, tumor necrosis, and mitotic activity) are the most important prognostic factors [18]. Differentiation between low- and high-grade STS is critical in treatment decision-making (in comparison to patients with low-grade STS, patients with high-grade STS have a worse outcome, develop metastases more frequently, and/or have a greater incidence of recurrent disease). Unfortunately, due to tumor heterogeneity, the preliminary tumor grading derived on biopsy specimens may differ from the final grade provided on the surgical specimen, leading to prognostic uncertainty and treatment delay [19, 20]. Recent studies suggest that cMRI can overcome this problem and MRI findings are concordant with prognostic information obtained from the histologic grade [11, 21, 22]. Furthermore, these MRI techniques have higher specificity in depicting tissue heterogeneity, which helps in guiding the biopsy [8]. Studies by Crombe et al. and Bologna et al. showed that features derived from cMRI (such as tumor heterogeneity, amount of necro-
sis, and peritumoral enhancement) are independent predictors of tumor grade and are associated with high-grade tumors [4, 22] (Fig. 2). A recent study by Lee et al. highlighted the added value of DWI in sarcoma imaging. By correlating DWI and DCE-MRI parameters with the Ki-67 labeling index (LI), the authors showed that the mean ADC value was significantly and inversely correlated with the Ki-67 LI ($\rho = -0.333$, $p = 0.047$). In contrast to the high-proliferation group of ST S, the low-proliferation group showed a significantly higher mean ADC value when a cut-off of $1.16 \times 10^{-3}$ mm$^2$/s was used, with a sensitivity, specificity, and area under the curve for differentiating low- and high-proliferation groups of 75.0 %, 60.0 %, and 0.712, respectively ($p = 0.014$). DCE-MRI parameters in the study did not show a statistically significant correlation with Ki-67 LI [23].

A relatively novel method in MSK radiology, i.e., MRS, yields information regarding the lesion's metabolism by measuring metabolites that are abundantly produced by malignant tumors, particularly choline (Cho)-containing compounds, enabling better tissue characterization and treatment response evaluation. Consequently, this method can differentiate benign from malignant soft-tissue tumors in pre-surgical and posttreatment settings [24]. Patel et al. showed that a discrete elevated Cho-peak could diagnose malignancy with a sensitivity and specificity of 88 % and 68 %, respectively. In comparison, a low concentration (< 0.3 mmol/kg) has a negative predictive value of 100 % for excluding malignancy [6]. In our opinion, the limitation and the most probable reason this method has not yet been implemented in standard practice is that it is technically challenging and has potential pitfalls. Specifically, an elevated Cho-peak can also be perceived in metabolically active benign lesions, such as peripheral nerve sheath tumors. Furthermore, as a marker of tissue damage, a lipid peak is observed in various conditions, including tumors after oncological treatment as well as inflammatory collections [8].

Bone sarcomas

Primary bone tumors account for less than 0.2 % of all cancers. They frequently affect the young population, in whom they exhibit an aggressive growth pattern and high mortality and disability rates. In general, osteosarcoma (OS) is the most common primary
malignant bone tumor, excluding malignancies of marrow origin, followed by chondrosarcoma (CS) and Ewing sarcoma (ES). The latter represents the second most common primary malignant bone tumor in children and adolescents. Compared to OS and ES, which mostly affect children and young adults, CS usually occurs in adult patients, most commonly in the fourth and fifth decade of life [1, 25–27] (Fig. 3).

The main objectives of imaging are to determine the size and the intramedullary extension of the lesion and the infiltration of the growth plate, muscle compartments, surrounding neurovascular structures, and joints, to detect skip lesions, to plan the optimal biopsy site, to establish the type of surgical resection, and to evaluate regional lymph node involvement.

An appropriate selection of various imaging techniques in the diagnostic workup of a patient with suspected primary bone sarcoma (BS) is essential for successful diagnosis and treatment [28]. An osteolytic or osteoblastic bone lesion, aggressive periosteal reaction, tumor matrix, and heterogeneous post-contrast enhancement are the key imaging features of malignant bone tumors. Nowadays, there are numerous noninvasive, technologically advanced imaging methods for evaluating BS, including CT, MRI, and nuclear imaging. However, radiographs of the entire bone in two orthogonal projections, together with the adjacent joint, remain essential for detecting skeletal lesions and should be obtained early in the diagnostic process in any symptomatic patient. For most osseous lesions, an appropriate differential diagnosis can be provided using the patient’s age, lesion location, and radiographic appearance [25–27, 29]. On CR, the bone destruction pattern (geographic vs. non-geographic), a zone of transition, cortical destruction, type of periosteal reaction, and soft-tissue and joint involvement are determined. These features help differentiate indolent from aggressive bone tumors [30] (Fig. 4).

While the role of CT in the local staging of BS has declined, it remains the standard method for evaluating uncertain radiographic and scintigraphy findings of the spine and pelvis. Due to its high sensitivity in detecting calcifications and ossifications, CT is preferable to CR for determining the tumor matrix and depicting occult matrix mineralization. Additionally, it allows better estimation of the depth and degree of endosteal scalloping [25, 26]. Infiltration of the growth plate and intra-articular extension can occur depending on the type of sarcoma and tumor growth rate. Although CT enables the detection of the changes surrounding the growth plate, it does not allow evaluation of physeal invasion as reliably as MRI (PPV, NPV, and accuracy were 81.5 %, 100 %, and 86.5 %, respectively, with CT in comparison to 87.1 %, 100 %, and 90.3 %, respectively, with MRI) [31].

In the diagnostic algorithm, MRI is the superior modality for detecting bone marrow infiltration and determining tumor extent, in agreement with the UICC/AJCC staging system [28, 32]. Although MRI has excellent specificity for classifying different subtypes of periosteal reaction [30], the lesion’s true nature and aggressiveness are much more accurately determined with CR. Consequently, MR images should always be assessed in combination with recent radiographs [33]. The MRI protocol has to include the entire tumor with the whole anatomical compartment and adjacent joints, as skip lesions greatly influence treatment planning [34]. An unenhanced T1-weighted MRI (T1 W) examination is essential to accurately determine the extent of a tumor before surgery. A study by Gulla et al. compared BS (OS, ES, and CS) measurements on MRI with the histopathological extent seen on resected specimens. For all BS types, the authors demonstrated a strong correlation between tumor size determined histopathologically after resection and the tumor size estimated by MRI preoperatively [35].

According to the American College of Radiology (ACR) Appropriateness Criteria for Bone Tumors, sufficiently high contrast between the tumor and healthy marrow on non-enhanced images enables optional intravenous (IV) administration of Gd in the evaluation of primary bone tumors [28]. With the help of CSI, a novel fast imaging technique, a marrow-replacing tumor can be identified and distinguished from a benign infiltrative process such as a bone marrow edema or hematopoietic marrow [36] (Fig. 5). Nevertheless, Gd application will better identify solid tumor areas, areas of necrosis, hemorrhage (necessary for biopsy planning), and joint involvement [3, 8, 37]. If not contraindicated, in our institution, we routinely perform additional postcontrast T1 W sequences on two planes.

As stated above, cMRI is currently the best imaging method for detecting and characterizing MSK tumors, but it cannot provide crucial information regarding tumorcellularity. In BS, an advanced sequence like DWI can evaluate tumorcellularity, primarily via quantifiable parameters like mean ADC, and therefore differentiate necrosis from viable tumor tissue, i.e., during response evaluation [5, 38]. Caution should be used when evaluating myxomatous, cystic, and cartilaginous components of primary BS, in which ADC values are significantly higher than those of other malignant bone tumors (Fig. 6). Regarding the sensitivity and specificity of DWI and ADC when differentiating benign from malignant primary BS, Rao et al. showed that CS had the highest ADC values, reaching as high as 2.99 × 10^{-3} mm²/s, while ES had the lowest ADC values, reaching as low as 0.56 × 10^{-3} mm²/s. The authors suggested that higher ADC value in CS might be due to cellularity variations within a cartilaginous stroma [38]. Not only in STS but also in BS, DWI can estimate the residual tumor tissue’s vitality after treatment and detect recurrence at an early stage when curative treatment is still possible [8].

MRS with metabolite quantification helps characterize primary bone lesions. In the literature, the sensitivity and specificity of MRS for detecting the Cho-compound in BS and STS are around 70 % and 75 %, respectively [39]. Malek et al. compared the DWI and multivoxel proton MRS findings in OS with those in normal muscle on a 3-Tesla MR system. The authors demonstrated that visual confirmation of diffusion restriction is sufficient for detecting tumor tissue without further need for quantification of ADC values. Furthermore, MRS showed a statistically higher maximum Cho/Cr ratio in OS than of normal muscle, 1.94 ± 1.12 vs. 1.34 ± 0.11, respectively [40].

As in STS, DCE-MRI in BS is used for tissue characterization, identifying areas of proliferating tumor tissue needed for biopsy, and monitoring response to neoadjuvant chemotherapy [41]. It shows encouraging results in post-therapeutic follow-up, distinguishing tumor from reactive edema after chemotherapy and residual tumor from postoperative granulation tissue [36]. Furthermore, in

Igrec J et al. Imaging of Bone... Fortschr Röntgenstr | © 2021. Thieme. All rights reserved.
Fig. 3  A 58-year-old male patient with high-grade chondrosarcoma of the femoral head and clear-cell chondrosarcoma of the acetabulum. Coronal T1-weighted sequence A shows an intermediate signal of the tumor in the femoral head with central low-signal areas corresponding to matrix calcification. The lesion in the acetabulum shows an intermediate to low signal. B Very high signal intensity is seen in non-mineralized portions of the tumors in axial fat-saturated T2-weighted sequence corresponding to cartilaginous matrix. C T1-weighted sequence after gadolinium application and additional subtraction image D show peripheral rim-like enhancement of the lesion in the femoral head (yellow arrow) and moderate heterogeneous contrast enhancement of the lesion in the acetabulum (green arrowhead). E DESS (Double Echo Steady State) sequence shows infiltration of the articular cartilage and the intraarticular extension of the femoral tumor (yellow star). F The lesions show no restricted diffusion on DWI- and ADC-map. G Corresponding axial CT, in bone window, the lesion in the femoral head shows cortical remodeling and extension to the cortex with permeative appearance. The pure osteolytic lesion in the acetabulum is seen with an intact cortex (hollow green arrow).

BS, DCE-MRI and DWI permit recognition of chemotherapy-induced tumor necrosis. In OS and ES, as a result of chemotherapy treatment, neo-angiogenesis decreases, subsequently causing necrosis, resulting in reduced tumor size with better tumor delineation from surrounding tissues [35, 37].

For patients with an absolute contraindication to MRI examination, dual-energy CT (DE-CT) may have a potential role in bone marrow imaging. It helps differentiate bone marrow edema from soft tissue infiltration, provides additional information regarding tissue composition, reduces metal artifacts, and optimizes image quality [42, 43].

Future outlook

Nowadays, attention is focused on developing hybrid systems that could enable a complete diagnostic evaluation for BS and STS in one session with the lowest possible radiation risk (significant in pediatric patients) [44]. Integrated PET/MRI is an evolving imaging modality, which combines the excellent soft-tissue contrast resolution of MRI with the functional metabolic capabilities of PET. This method has yielded encouraging results with respect to improving staging, preoperative and radiation therapy planning, and the evaluation of treatment response while decreasing cumulative radiation dose in children as well as in adult patients with sarcoma [45, 46]. Further studies are needed to establish its definitive future role.

The introduction of artificial intelligence (AI) in MSK radiology and the employment of radiomic texture analysis have resulted in the development of radiomic MRI-based models that could help distinguish low-grade from high-grade sarcomas [47, 48]. In a study by Malinauskaite et al., radiomics incorporated with machine-learning methods performed better than specialized MSK radiologists, reaching a diagnostic accuracy of 94.7% [49]. Additionally, radiomic features extracted from MRI show promise as biomarkers for predicting overall survival in patients with STS. In the future, combining models using clinical and radiomic features could optimize treatment and enable personalized management of patients with sarcoma [50].

Conclusion

The incorporation of various imaging modalities in the diagnostic algorithm for mesenchymal tumors has contributed to the improvement of the diagnosis, surgical planning, and assessment of oncological therapy effectiveness. The role of MRI in the evaluation of MSK tumors continues to evolve while new hybrid tech-
Fig. 5 Parosteal osteosarcoma of the distal humerus G2 in a 57-year-old female patient. On T1-weighted sequence A, the lesion is relatively hyperintense with respect to muscle. The low signal is also seen in the medullary canal, initially suspicious for bone marrow infiltration (arrow). B Heterogeneous high signal on T2-weighted sequence with a focal high signal of the underlying cortex and medulla (arrowhead). The lesion shows diffusion restriction on DWI C and ADC map D with no intramedullary restricted diffusion (white arrow). E Typical choline peak (hollow arrow) is seen on MR spectroscopy confirming the lesion's malignant nature. F-i Dixon QCSI sequences (asterisk) allow the exclusion of bone marrow infiltration.

Fig. 6 Classic osteosarcoma of the proximal tibial metaphysis in a 47-year-old male patient. A Intraosseous (yellow asterisk) and extraosseous (white asterisk) extension of the tumor are seen on sagittal T1-weighted sequence. B, C Chemical shift imaging shows sharp delineation of the tumor and surrounding normal bone marrow with "India-ink artifact" on opposed phase (yellow arrow). D Corresponding axial CT of the lower extremities in the bone window shows osteodestructive lesion in the medial proximal tibial metaphysis (circle). Diffusion restriction of the osteosarcoma is seen on DWI and ADC maps E, F, G Post-gadolinium T1-weighted sequence shows heterogeneous enhancement of the tumor with hypovascularized tumor tissue centrally.
niques develop concurrently. Although cMRI is currently the state-of-the-art method for the characterization of bone and soft-tissue lesions, aMRI methods have become available and, in the future, have the potential to become the gold standard in sarcoma imaging. A shift from classic radiological image analysis toward radiomics – based on the extraction of radiomic features from data sets provided by CR, US, CT, and MRI – has the potential to positively impact clinical decision-making and the treatment management of patients with STS and BS.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**References**


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


[50] Spraker MB, Wootton LS, Hippe DS et al. MRI radiomic features are independently associated with overall survival in soft tissue sarcoma. Advances in radiation oncology 2019; 4: 413–421